Abstract
We conducted a cohort study of acute, noninfectious liver injury among oral antimicrobial users. Potential cases were identified in the HealthCore Integrated Research Database (HIRDSM) population between July 1, 2001, and March 31, 2009, using ICD-9-CM codes primarily for acute and subacute necrosis of the liver, hepatic coma, and unspecified hepatitis.
Liver test results were used to confirm case status according to published criteria. Two physician reviewers experienced in studying acute liver injury (blinded to study drug exposures) evaluated data abstracted from hospital and emergency department records to validate potential cases. Of 715 potential cases having claims associated with any of the primary screening codes, 312 (44%) were valid cases, 108 (15%) were not cases, and 295 (41%) were of uncertain status (records inadequate for validation). Among potential cases with adequate medical records, the PPV for presence of any of the primary codes was 74% (95% CI, 70%-78%). The highest PPV for a single code was for acute and subacute necrosis of the liver (84%; 95% CI, 77%-90%).
Evaluation of cases of noninfectious liver injury using hospital and emergency department medical records continues to represent the preferred approach in studies using insurance claims data.
Keywords: Antimicrobials, cohort, liver injury, nested case-control, validation.
Current Drug Safety
Title:Validation of Acute Liver Injury Cases in a Population-Based Cohort Study of Oral Antimicrobial Users
Volume: 9 Issue: 1
Author(s): Christine L. Bui, James A. Kaye, Jordi Castellsague, Brian Calingaert, Lisa J. McQuay, Nuria Riera-Guardia, Catherine W. Saltus, Scott C. Quinlan, Crystal N. Holick, Peter M. Wahl, Kiliana Suzart, Kenneth J. Rothman, Mari-Ann Wallander and Susana Perez-Gutthann
Affiliation:
Keywords: Antimicrobials, cohort, liver injury, nested case-control, validation.
Abstract: We conducted a cohort study of acute, noninfectious liver injury among oral antimicrobial users. Potential cases were identified in the HealthCore Integrated Research Database (HIRDSM) population between July 1, 2001, and March 31, 2009, using ICD-9-CM codes primarily for acute and subacute necrosis of the liver, hepatic coma, and unspecified hepatitis.
Liver test results were used to confirm case status according to published criteria. Two physician reviewers experienced in studying acute liver injury (blinded to study drug exposures) evaluated data abstracted from hospital and emergency department records to validate potential cases. Of 715 potential cases having claims associated with any of the primary screening codes, 312 (44%) were valid cases, 108 (15%) were not cases, and 295 (41%) were of uncertain status (records inadequate for validation). Among potential cases with adequate medical records, the PPV for presence of any of the primary codes was 74% (95% CI, 70%-78%). The highest PPV for a single code was for acute and subacute necrosis of the liver (84%; 95% CI, 77%-90%).
Evaluation of cases of noninfectious liver injury using hospital and emergency department medical records continues to represent the preferred approach in studies using insurance claims data.
Export Options
About this article
Cite this article as:
Bui L. Christine, Kaye A. James, Castellsague Jordi, Calingaert Brian, McQuay J. Lisa, Riera-Guardia Nuria, Saltus W. Catherine, Quinlan C. Scott, Holick N. Crystal, Wahl M. Peter, Suzart Kiliana, Rothman J. Kenneth, Wallander Mari-Ann and Perez-Gutthann Susana, Validation of Acute Liver Injury Cases in a Population-Based Cohort Study of Oral Antimicrobial Users, Current Drug Safety 2014; 9 (1) . https://dx.doi.org/10.2174/15748863113086660051
DOI https://dx.doi.org/10.2174/15748863113086660051 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
Current Cardiology Reviews ATP Citrate Lyase Inhibitors as Novel Cancer Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Subacute Fluoxetine Reduces Signs of Hippocampal Damage Induced by a Single Convulsant Dose of 4-Aminopyridine in Rats
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Modifying Cardiovascular Risk Factors: Epidemiology and Characteristics of Hypertension-Related Disorders (Executive Guest Editor: Aurelio Leone)]
Current Pharmaceutical Design Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Obstructive Sleep Apnea Syndrome: Implications in Cardiovascular Disease
Current Respiratory Medicine Reviews Rationale and Design of the ACS-BP Study: Prognostic Value of In-Hospital Blood Pressure and Indices of Atherosclerosis in Acute Coronary Syndromes
Current Vascular Pharmacology Editorial: [Aliskiren/Amlodipine Single-Pill Combinations: More Evidence in Favour of Combination Formulations for the Treatment of Hypertension]
Current Vascular Pharmacology Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry Historical Aspects and Relevance of the Human Coronary Collateral Circulation
Current Cardiology Reviews Nano-Tetrandrine Efficiently Inhibits the Proliferation and Induces the Apoptosis of Hep2 Cells through a Mitochondrial Signaling Pathway
Current Signal Transduction Therapy The Effect of Borage (Echium amoenum) on the Mouse Heart and Hematology Parameters
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Options and Emerging Alternatives for Multidrug Resistant Staphylococcal Infections
Current Pharmaceutical Design Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
Current Gene Therapy Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets Calreticulin in the Heart: From Embryological Development to Cardiac Pathology.
Current Molecular Medicine Angiotensin II Blockade and Renal Protection
Current Pharmaceutical Design Integrative Physiology of Orexins and Orexin Receptors
CNS & Neurological Disorders - Drug Targets The ACE2-Ang-(1-7)-Mas Axis and Cardioprotection
Current Cardiology Reviews Obesity, Hypertension and Hypercholesterolemia as Risk Factors for Atherosclerosis Leading to Ischemic Events
Current Medicinal Chemistry